GMAB News and Press, Genmab A/S From 05/11/24

2024-05-11 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-06 09:50:37 ET Summary Regeneron is not having a great start to 2024 as the company missed Q1 revenue and EPS estimates and received two complete response letters from the FDA for odronextamab. First quarter results were negatively impacted by lower-than-expected collabora...

2024-05-02 18:05:20 ET Genmab A/S (GMAB) Q1 2024 Earnings Conference Call May 2, 2024 12:00 PM ET Company Participants Jan van de Winkel – Chief Executive Officer Anthony Mancini – Chief Operating Officer Anthony Pagano – Chief Financial Offi...

May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

2024-05-01 14:28:01 ET More on Genmab Genmab: A Complicated Tale Genmab Acquires A Missing Piece For Its Pipeline Genmab: Recent Updates Support The Growth Narrative Pfizer, Genmab cervical cancer therapy wins full FDA approval Genmab to purchase US-b...

2024-05-01 11:22:41 ET Major earnings expected before the bell on Thursday include: ConocoPhillips ( COP ) Iron Mountain ( IRM ) Moderna ( MRNA ) Organon ( OGN ) Shell ( SHEL ) Read the full article on Seeking Alpha For further details...

2024-05-01 10:27:47 ET Summary Genmab's stock has lost over 35% of its value since December 2022 due to unfavorable arbitration cases and high spending on launching Epkinly. The company's top line is currently dominated by royalties from Darzalex, but it hopes Epkinly will contrib...

2024-04-30 06:26:54 ET Pfizer ( NYSE: PFE ) and Danish drugmaker Genmab ( GMAB ) announced Monday that the U.S. FDA accepted a supplemental Biologics License Application granting full approval for their cervical cancer therapy, Tivdak (tisotumab vedotin-tftv).... Read ...

TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer Conversion to full approval from accelerated approval is based on positive results from global Phase 3 study demonstrating ...